Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Basal Insulin Use in the Non-Critical Care Setting: Is Fasting Hypoglycemia Inevitable or Preventable?

Flory JH, Aleman JO, Furst J, Seley JJ.

J Diabetes Sci Technol. 2014 Mar;8(2):427-428. Epub 2014 Jan 21. No abstract available.

2.
3.

Addressing hyperglycemia from hospital admission to discharge.

Moghissi ES.

Curr Med Res Opin. 2010 Mar;26(3):589-98. doi: 10.1185/03007990903566822. Review.

PMID:
20078323
4.

Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.

Smiley D, Umpierrez GE, Hermayer K, Newton C, Jacobs S, Olson DE, Khan A, Rizzo M, Peng L, Reyes D, Cardona S, Fonseca V.

J Diabetes Complications. 2013 Nov-Dec;27(6):637-41. doi: 10.1016/j.jdiacomp.2013.05.007. Epub 2013 Aug 1.

5.

Hypoglycemia in non-critically ill, hospitalized patients with diabetes: evaluation, prevention, and management.

Rubin DJ, Golden SH.

Hosp Pract (1995). 2013 Feb;41(1):109-16. doi: 10.3810/hp.2013.02.1016. Review.

PMID:
23466973
6.
7.
8.

Intensive insulin protocol implementation and outcomes in the medical and surgical wards at a Veterans Affairs Medical Center.

Chen HJ, Steinke DT, Karounos DG, Lane MT, Matson AW.

Ann Pharmacother. 2010 Feb;44(2):249-56. doi: 10.1345/aph.1M501. Epub 2010 Jan 26.

PMID:
20103610
9.

Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.

Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S; PREDICTIVE Turkey Study Group.

Pediatr Diabetes. 2009 Sep;10(6):401-7. doi: 10.1111/j.1399-5448.2008.00497.x. Epub 2009 Feb 11.

PMID:
19220776
10.

Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin.

Kudva YC, Basu A, Jenkins GD, Pons GM, Vogelsang DA, Rizza RA, Smith SA, Isley WL.

Endocr Pract. 2007 May-Jun;13(3):244-50.

PMID:
17599855
11.

Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.

Oster G, Sullivan SD, Dalal MR, Kazemi MR, Rojeski M, Wysham CH, Sung J, Johnstone B, Cali AM, Wei LJ, Traylor L, Anhalt H, Hull M, Van Vleet J, Meneghini LF.

Postgrad Med. 2016 Nov;128(8):731-739. Epub 2016 Oct 24.

PMID:
27690710
12.

Glycemic management in the inpatient setting.

Schmeltz LR, Ferrise C.

Hosp Pract (1995). 2012 Apr;40(2):44-55. doi: 10.3810/hp.2012.04.969. Review.

PMID:
22615078
14.
17.

Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes.

Farrokhi F, Klindukhova O, Chandra P, Peng L, Smiley D, Newton C, Pasquel F, Fereira ME, Umpierrez G.

J Diabetes Sci Technol. 2012 Sep 1;6(5):1022-9.

18.

Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data.

Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH.

Diabetes Technol Ther. 2012 Nov;14(11):1008-12. doi: 10.1089/dia.2012.0099.

PMID:
23101951
19.

Hypoglycemia as a barrier to glycemic control.

Davis S, Alonso MD.

J Diabetes Complications. 2004 Jan-Feb;18(1):60-8. Review.

PMID:
15019602
20.

Optimizing inpatient glycemic control with basal-bolus insulin therapy.

Pollom RD.

Hosp Pract (1995). 2010 Nov;38(4):98-107. doi: 10.3810/hp.2010.11.346.

PMID:
21068533

Supplemental Content

Support Center